EP2342569A4 - Screening method for identifying patients at risk of adverse hepatologic events - Google Patents

Screening method for identifying patients at risk of adverse hepatologic events

Info

Publication number
EP2342569A4
EP2342569A4 EP09810686A EP09810686A EP2342569A4 EP 2342569 A4 EP2342569 A4 EP 2342569A4 EP 09810686 A EP09810686 A EP 09810686A EP 09810686 A EP09810686 A EP 09810686A EP 2342569 A4 EP2342569 A4 EP 2342569A4
Authority
EP
European Patent Office
Prior art keywords
hepatologic
adverse
events
risk
screening method
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP09810686A
Other languages
German (de)
French (fr)
Other versions
EP2342569A2 (en
Inventor
Russell Medford
Kenneth M Borow
Hilda Maibach
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Salutria Pharmaceuticals LLC
Original Assignee
Salutria Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salutria Pharmaceuticals LLC filed Critical Salutria Pharmaceuticals LLC
Publication of EP2342569A2 publication Critical patent/EP2342569A2/en
Publication of EP2342569A4 publication Critical patent/EP2342569A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Emergency Medicine (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP09810686A 2008-08-28 2009-08-28 Screening method for identifying patients at risk of adverse hepatologic events Withdrawn EP2342569A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9268608P 2008-08-28 2008-08-28
PCT/US2009/055430 WO2010025410A2 (en) 2008-08-28 2009-08-28 Screening method for identifying patients at risk of adverse hepatologic events

Publications (2)

Publication Number Publication Date
EP2342569A2 EP2342569A2 (en) 2011-07-13
EP2342569A4 true EP2342569A4 (en) 2012-07-04

Family

ID=41722327

Family Applications (1)

Application Number Title Priority Date Filing Date
EP09810686A Withdrawn EP2342569A4 (en) 2008-08-28 2009-08-28 Screening method for identifying patients at risk of adverse hepatologic events

Country Status (5)

Country Link
EP (1) EP2342569A4 (en)
JP (1) JP2012501454A (en)
CN (1) CN102257389A (en)
CA (1) CA2735582A1 (en)
WO (1) WO2010025410A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2658374T3 (en) * 2010-12-30 2016-01-25 Muhammed Majeed Hepatoprotective effect of garcinol
WO2012122024A2 (en) * 2011-03-04 2012-09-13 Russell Medford Screening method for identifying patients at risk of drug induced liver injury
CN103376323A (en) * 2012-04-25 2013-10-30 中国科学院上海生命科学研究院 Application of apolipoprotein C-III as marker of obesity-diabetes
CN103063848B (en) * 2012-12-26 2015-06-03 潍坊三维生物工程集团有限公司 Kit for determination of apolipoprotein C2 by using immunoturbidimetry
JP7153019B2 (en) * 2016-12-14 2022-10-13 エフ．ホフマン－ラ ロシュ アーゲー Determination of interfering substances in samples
EP3373012A1 (en) 2017-03-07 2018-09-12 Biopredictive Method of diagnosis of drug induced liver injury
CN110780071A (en) * 2019-11-11 2020-02-11 彭涛 Hepatitis B-related hepatocellular carcinoma prognosis detection kit
CN120600339B (en) * 2025-08-05 2025-09-30 中国人民解放军空军军医大学 Method and system for detecting hepatotoxicity of antifungal drug

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030003501A1 (en) * 1999-03-16 2003-01-02 Judith Fitzpatrick Method and device for detection of apo a, apo b and the ratio thereof in saliva
FR2870349A1 (en) * 2004-05-14 2005-11-18 Univ Angers METHOD FOR DIAGNOSING THE PRESENCE AND / OR SEVERITY OF A HEPATIC PATHOLOGY IN A SUBJECT AND / OR FOR MONITORING THE EFFECTIVENESS OF TREATMENT OF SUCH A PATHOLOGY
US20060172286A1 (en) * 2005-02-03 2006-08-03 Thierry Poynard Diagnosis method of alcholic or non-alcoholic steato-hepatitis using biochemical markers

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5500375A (en) 1993-04-13 1996-03-19 Serex, Inc. Integrated packaging-holder device for immunochromatographic assays in flow-through or dipstick formats
EP0710288B1 (en) * 1993-06-10 2006-04-05 Genetic Therapy, Inc. Adenoviral vectors for treatment of hemophilia
US6107045A (en) 1994-06-30 2000-08-22 Oklahoma Medical Research Foundation Antibodies to lipoproteins and apolipoproteins and methods of use thereof
JP2004123716A (en) * 2002-08-06 2004-04-22 Mitsubishi Pharma Corp Pharmaceutical for prevention and / or treatment of liver damage caused by chemical substances
US7517951B2 (en) * 2002-12-24 2009-04-14 Nitto Boseki Co., Ltd. Marker proteins for diagnosing liver disease and method of diagnosing liver disease using the same
WO2005002505A2 (en) * 2003-05-23 2005-01-13 Johns Hopkins University Apolipoprotein c-1 induced apoptosis
US7860656B2 (en) * 2005-02-03 2010-12-28 Assistance Publique-Hopitaux De Paris (Ap-Hp) Diagnosis method of hepatic steatosis using biochemical markers
EP1726962A1 (en) * 2005-05-24 2006-11-29 Leiden University Medical Center Apolipoprotein E plasma levels for monitoring and reducing the risk of cardiovascular disease

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030003501A1 (en) * 1999-03-16 2003-01-02 Judith Fitzpatrick Method and device for detection of apo a, apo b and the ratio thereof in saliva
FR2870349A1 (en) * 2004-05-14 2005-11-18 Univ Angers METHOD FOR DIAGNOSING THE PRESENCE AND / OR SEVERITY OF A HEPATIC PATHOLOGY IN A SUBJECT AND / OR FOR MONITORING THE EFFECTIVENESS OF TREATMENT OF SUCH A PATHOLOGY
US20060172286A1 (en) * 2005-02-03 2006-08-03 Thierry Poynard Diagnosis method of alcholic or non-alcoholic steato-hepatitis using biochemical markers

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2010025410A2 *

Also Published As

Publication number Publication date
WO2010025410A3 (en) 2010-07-01
JP2012501454A (en) 2012-01-19
WO2010025410A2 (en) 2010-03-04
CN102257389A (en) 2011-11-23
CA2735582A1 (en) 2010-03-04
EP2342569A2 (en) 2011-07-13

Similar Documents

Publication Publication Date Title
IL239277A0 (en) Method of identifying disease risk factors
GB2471805B (en) Method for trouble managing of equipment
GB0810051D0 (en) Method of diagnosis
SI3093663T1 (en) Predicting risk of major adverse cardiac events
GB0906698D0 (en) Method for quantifying modified peptides
IL209212A0 (en) Integrated heart monitoring nethod of using same
EP2029771A4 (en) Diagnostic method for myopathy
IL242391A (en) Method of identifying risk for thyroid disorder
PL2002702T3 (en) Method for pre-germinating seed
GB2474319B (en) Method and system for analysing tissue from images
EP2287604A4 (en) Method for examination of alzheimer s disease
TWI365420B (en) Method for defect diagnosis and management
GB0912992D0 (en) Method of screening for pathogens
EP2438194A4 (en) Methods for screening and identifying compounds
ZA201008471B (en) Biomarker for selecting patients and related methods
EP2218492A4 (en) METHOD FOR REMOVAL OF ClO3F
TWI350162B (en) Method of multiple-subject image analysis using brain atlas
IL190526A0 (en) Method for identifying patients
HU0800345D0 (en) Method for monitoring bone neogenesis
GB0710980D0 (en) Method of analysis
GB0800563D0 (en) Method for removal of contamination
AP2009004920A0 (en) Method of collecting seeds
GB0906222D0 (en) Methods for screening of therapeutic agents
GB0801084D0 (en) Screening method
GB0810716D0 (en) Method of analysis

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20110316

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

AX Request for extension of the european patent

Extension state: AL BA RS

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20120601

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 3/10 20060101ALI20120525BHEP

Ipc: G01N 33/15 20060101ALI20120525BHEP

Ipc: G01N 33/68 20060101AFI20120525BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20111123

R18D Application deemed to be withdrawn (corrected)

Effective date: 20130103